The cohort of post-menopausal women represents a group of very-difficult-to-treat patients in
whom a more powerful approach is required in order to improve the disappointing response
rate. Thus the addition, in patients with previous failure to PEG/RBV treatment or in naïve
patients, of a powerful drug like Boceprevir could greatly improve SVR rate as suggested by
the results of SPRINT_2 trial in whom Boceprevir addition determined a 30% improvement in SVR
rate in difficult gt 1 patients of African descent versus standard PEG IFN/Ribavirin therapy
or by those of RESPOND-2 that showed the same percent improvement of RGT-retreatment with
Boc/P/R of previous failure of standard therapy.
Goal of the study is to verify whether the addition of a 24-week treatment with boceprevir to
standard antiviral therapy with Peg IFN and ribavirin will increase the rate of SVR in
patients difficult to treat, such as HCV-positive women in post-menopausal women with
genotype 1, not only those who have never been treated, but also in those who have not
responded to previous treatment with peginterferon and ribavirin (Riba).